A multicenter, prospective, randomized, open-label, blinded endpoint trial of intravenous thrombolysis with tenecteplase for acute non-large vessel occlusion in extended time window (OPTION): Rationale and design
The OPTION trial (NCT05752916) will provide evidence regarding the efficacy and safety of tenecteplase 4.5 to 24 hours in patients with AIS due to non-LVO.
Authors
- Shaoyuan Lei
- Gaoting Ma (ORCID: https://orcid.org/0000-0002-9374-7589)
- Qingfeng Ma (ORCID: https://orcid.org/0000-0002-1676-3235)
- Yifan Wu (ORCID: https://orcid.org/0000-0001-9581-7803)
- Junwei Hao (ORCID: https://orcid.org/0000-0002-3075-5434)
- Ziying Jiang (ORCID: https://orcid.org/0009-0001-0484-1611)
- Ran Mo (ORCID: https://orcid.org/0000-0003-4010-8879)
- Jeffrey L. Saver (ORCID: https://orcid.org/0000-0001-9141-2251)
- Yingting Zuo (ORCID: https://orcid.org/0000-0002-8113-8276)
- Thanh N. Nguyen
- Jieying Wu (ORCID: https://orcid.org/0000-0001-5964-4554)
- Lianmei Zhong
- Shujuan Meng
- Duolao Wang (ORCID: https://orcid.org/0000-0003-2788-2464)
Institutions
- Boston Medical Center (US)
- Ministry of Education of the People's Republic of China (CN)
- Capital Medical University (CN)
- Liverpool School of Tropical Medicine (GB)
- UCLA Health (US)
- Beijing Municipal Engineering Design and Research Institute (China) (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1515/jtim-2025-0048
- Citations
- 2
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 2.71